“…Studies have shown that IL‐13 contributes to the pathogenesis of fibroproliferative diseases, such as pulmonary fibrosis, liver cirrhosis, myocardial fibrosis, progressive kidney disease and pathological skin scarring, among others 11–14 . Furthermore, IL‐13 was associated with elevated production of total collagens in normal human skin and keloid fibroblasts (FBs), whereas FBs in various scarring diseases produced more fibrin, suggesting that IL‐13 is associated with fibrosis 15–17 . Interestingly, a recent report demonstrated that in fibrosis, inhibition of both IL‐13 and TGF‐β signalling completely attenuated the fibrotic mechanism compared to TGF‐β inhibition alone 18 …”